MD Medical Group
MD Medical Group was paid $993K by Medicaid between Apr 2021 and Mar 2023, across 14 billing codes. Its largest line is 87426, Infectious agent antigen detection, SARS-CoV-2 (COVID-19) — 82% of everything it billed.
33Billing provider infoMD MEDICAL GROUP
ATLANTIC HIGHLANDS, NJ 07716
ATLANTIC HIGHLANDS, NJ 07716
33aNPI1982280426assigned 03/23/2021
33bProvider typeCommunity Health Worker
28Total paid$993K
24GClaims91,006
24DCodes billed14
24AFirst – last monthApr 2021 – Mar 2023
Compared with peers
Next to other Community Health Worker providers in New Jersey
Rank by total paid#4 of 7
Median peer was paid$993K
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 36,061 | $379K | |
| 2022 | 53,440 | $592K | |
| 2023 | 1,505 | $22K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 82% | 34,081 | 22,923 | $813K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | 6.8% | 2,908 | 2,193 | $68K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 6.5% | 41,391 | 24,951 | $65K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.5% | 6,068 | 2,208 | $25K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.2% | 619 | 470 | $12K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 494 | 365 | $8K |
| 99072 | <1% | 5,307 | 4,165 | $195.66 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 21 | 20 | $163.00 |
| 0003A | <1% | 18 | 16 | $160.00 | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 18 | 12 | $158.74 |
| 87807 | <1% | 36 | 34 | $101.58 | |
| 91307 | <1% | 14 | 14 | $0.12 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWICKERSHAM, DAVID (JR MEMBER)